Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Buy now fake rolex


MSD sues over access program

Posted 22 July 2021 AM

Oncology giants MSD and BMS are going head-to-head in the Federal Court over patients' right to access a BMS compassionate program.

The dispute is unlike any previously seen between two big pharmas as MSD tries to force BMS to open its Opdivo Melanoma Continuation Program (MCP) to patients who have previously been treated with Keytruda, an MSD product.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Top of the Hill
Pitfalls may plague NMP review
With an election in play, will it arrive too late?
Approvals Action
First copy of Halaven ticked
Along with other generics of already PBS-listed drugs